Fresh frozen plasma (FFP) is the primary blood product indicated to replace clotting factors. It contains approximately 1 IU/mL of every coagulation factor, making it the most comprehensive option when multiple factors need replenishing at once. However, FFP isn’t the only choice. Depending on which factors are deficient and how urgently they’re needed, other products like cryoprecipitate, prothrombin complex concentrates, or individual factor concentrates may be more appropriate.
Fresh Frozen Plasma: The Broad Replacement
FFP is plasma separated from whole blood and frozen within hours of collection. It replenishes fibrinogen, prothrombin, and factors V, VII, IX, and X, along with every other clotting protein. Because it covers all factors simultaneously, it’s the go-to product when the specific deficiency isn’t known or when multiple factors are low at once.
The standard indications for FFP include active bleeding with abnormal coagulation tests, planned surgery when clotting tests are off, warfarin reversal when vitamin K alone won’t work fast enough, and congenital or acquired factor deficiencies when no specific concentrate is available. It’s also used therapeutically in thrombotic thrombocytopenic purpura (TTP).
One practical limitation: FFP must be thawed before use, which takes time. Each unit is about 250 mL, and typical dosing runs 10 to 30 mL per kilogram of body weight. For an average adult, that can mean transfusing several units, which adds up to a significant fluid volume. That matters for patients with heart failure or kidney problems who can’t tolerate large volumes safely.
How Clotting Factors Degrade After Thawing
Once FFP is thawed, the clock starts ticking on factor activity. Factor VIII is the most fragile. It drops from roughly 70% activity at baseline to about 40 to 45% within 24 hours, then settles around 37 to 40% by day three with no further meaningful recovery. Factor V holds up better, staying near 71 to 73% at 24 hours and around 66% through day five. All other factors generally remain above 50% activity through five days of refrigerated storage. The takeaway: if factor VIII replacement is the goal, freshly thawed plasma is significantly more effective than plasma that’s been sitting in the fridge.
Cryoprecipitate: Concentrated Fibrinogen and Factor VIII
Cryoprecipitate is made from plasma but concentrated into a much smaller package, typically 15 to 20 mL per unit. Each unit delivers 150 to 250 mg of fibrinogen along with meaningful amounts of factor VIII, von Willebrand factor, factor XIII, and fibronectin.
It’s used when fibrinogen levels are critically low (a common problem in massive bleeding, liver disease, or disseminated intravascular coagulation) and when the volume of FFP needed to raise fibrinogen would be excessive. Think of cryoprecipitate as a targeted tool: it doesn’t replace all clotting factors the way FFP does, but it delivers specific ones in a concentrated, low-volume form.
Prothrombin Complex Concentrates: Faster Warfarin Reversal
Prothrombin complex concentrates (PCCs) are freeze-dried products that contain high levels of the vitamin K-dependent clotting factors. The 4-factor version includes factors II, VII, IX, and X, while 3-factor versions leave out factor VII. The American College of Cardiology recommends 4-factor PCC as the preferred product for reversing warfarin-related bleeding.
PCC has several practical advantages over FFP in emergency situations. A single dose of PCC delivers the equivalent of 8 to 16 units of FFP, compressed into roughly 20 mL of fluid instead of thousands of milliliters. It can be infused in 15 to 30 minutes, doesn’t require thawing, and is safer for patients who can’t handle large fluid loads. In one major trial, 28 out of 29 patients receiving PCC achieved normal clotting values, while 12 patients receiving FFP did not.
The tradeoff is narrower coverage. PCC only replaces the four vitamin K-dependent factors. It won’t help with factor V deficiency, fibrinogen problems, or other clotting protein shortfalls. It also carries a small risk of blood clots as a complication.
Specific Factor Concentrates for Hemophilia
When a single clotting factor is missing, as in hemophilia, targeted factor concentrates are far more effective than broad products like FFP. Hemophilia A (factor VIII deficiency) is treated with either plasma-derived or laboratory-made (recombinant) factor VIII concentrates. Hemophilia B (factor IX deficiency) is treated with factor IX concentrates.
Recombinant products are manufactured without human or animal plasma proteins, which reduces infection risk. For factor VIII, plasma-derived and recombinant versions perform similarly in the body. For factor IX, the recombinant version has about 30% lower recovery in the bloodstream compared to the plasma-derived form, which affects dosing. Rates of inhibitor development (an immune reaction that makes the treatment less effective) appear similar between plasma-derived and recombinant products based on large studies.
Choosing the Right Product
The decision depends on three things: which factors are missing, how urgently they’re needed, and how much fluid the patient can tolerate.
- Multiple or unknown factor deficiencies with bleeding: FFP is the standard choice because it covers everything.
- Low fibrinogen specifically: Cryoprecipitate delivers concentrated fibrinogen in a small volume.
- Warfarin reversal with life-threatening bleeding: 4-factor PCC works faster, in less volume, and more reliably than FFP.
- Single factor deficiency (hemophilia): Specific factor concentrates provide precise, high-dose replacement without unnecessary components.
- Massive trauma bleeding: Current protocols use FFP alongside red blood cells and platelets in balanced ratios, typically between 1:1:1 and 1:1:2 (plasma to platelets to red cells), which has been linked to lower mortality.
Risks of Plasma-Based Products
All plasma-containing blood products carry some risk. Transfusion-related acute lung injury (TRALI), a sudden inflammatory reaction in the lungs, occurs in roughly 1 in 2,000 plasma-containing transfusions. Volume overload is another concern, particularly with FFP, since replacing clotting factors often requires large volumes. Allergic reactions, fever, and (rarely) transmission of infections are also possible. PCC, being leukocyte-free and low-volume, generally carries a lower risk of infusion reactions but introduces a small clotting risk of its own.